...
首页> 外文期刊>Journal of endourology >Alternative therapeutic approach to renal-cell carcinoma: Induction of apoptosis with combination of vitamin K3 and D-fraction
【24h】

Alternative therapeutic approach to renal-cell carcinoma: Induction of apoptosis with combination of vitamin K3 and D-fraction

机译:肾细胞癌的替代治疗方法:维生素K3和D级分联合诱导凋亡

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Because of a dismal prognosis for advanced renal-cell carcinoma (RCC), an alternative therapeutic approach, using vitamin K3 (VK 3) and D-fraction (DF) was investigated. VK3 is a synthetic VK derivative and DF is a bioactive mushroom extract, and they have been shown to have antitumor activity. We examined if the combination of VK 3 and DF would exhibit the improved anticancer effect on RCC in vitro. Materials and Methods: Human RCC, ACHN cell line, were treated with varying concentrations of VK3, DF, or a combination of the two. Cell viability was assessed at 72 hours by MTT assay. To explore the possible anticancer mechanism, studies on cell cycle, chromatin modifications, and apoptosis were conducted. Results: VK3 alone led to a ~20% reduction in cell viability at 4 μM, while DF alone induced a 20% to 45% viability reduction at ≥500 μg/mL. A combination of VK3 (4 μM) and DF (300 μg/mL) led to a drastic 90% viability reduction, however. Cell cycle analysis indicated that VK3/DF treatment induced a G1 cell cycle arrest, accompanied by the up-regulation of p21 WAF1 and p27Kip1. Histone deacetylase (HDAC) was also significantly (~60%) inactivated, indicating chromatin modifications. In addition, Western blot analysis revealed that the up-regulation of Bax and activation of poly-(ADP-ribose)-polymerase (PARP) were seen in VK 3/DF-treated cells, indicating induction of apoptosis. Conclusions: The combination of VK3 and DF can lead to a profound reduction in ACHN cell viability, through a p21WAF1-mediated G1 cell cycle arrest, and ultimately induces apoptosis. Therefore, the combination of VK3/DF may have clinical implications as an alternative, improved therapeutic modality for advanced RCC.
机译:目的:由于晚期肾细胞癌(RCC)的预后不良,因此研究了使用维生素K3(VK 3)和D级分(DF)的另一种治疗方法。 VK3是合成的VK衍生物,而DF是具有生物活性的蘑菇提取物,已显示它们具有抗肿瘤活性。我们检查了VK 3和DF的组合是否在体外对RCC表现出改善的抗癌作用。材料和方法:用不同浓度的VK3,DF或两者结合处理人RCC,ACHN细胞系。通过MTT分析在72小时评估细胞生存力。为了探索可能的抗癌机制,进行了细胞周期,染色质修饰和凋亡的研究。结果:在4μM时,单独的VK3导致细胞活力降低约20%,而在≥500μg/ mL时,单独的DF导致细胞活力降低20%至45%。但是,VK3(4μM)和DF(300μg/ mL)的组合导致活力大大降低> 90%。细胞周期分析表明,VK3 / DF处理可诱导G1细胞周期停滞,并伴随p21 WAF1和p27Kip1的上调。组蛋白脱乙酰基酶(HDAC)也显着失活(〜60%),表明染色质被修饰。另外,蛋白质印迹分析显示在VK 3 / DF处理的细胞中观察到Bax的上调和聚-(ADP-核糖)-聚合酶(PARP)的激活,表明细胞凋亡的诱导。结论:VK3和DF的组合可通过p21WAF1介导的G1细胞周期阻滞,导致ACHN细胞活力大幅降低,并最终诱导细胞凋亡。因此,VK3 / DF的组合作为晚期RCC的替代,改进的治疗方式可能具有临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号